Dr. OZLEM APTI SENGKIOUN

Cosmetic Dermatology , Dermatology

Education

• 2022Marmara University Faculty of Medicine, Department of Skin and Venereal Diseases
• 2017Istanbul University Cerrahpasa Medical Faculty

Experience

• 2023Acıbadem Health Group
• 2018 – 2022Marmara University Faculty of Medicine / Department of Skin and Venereal Diseases /

Memberships

• European Academy of Dermatology and Venereology
• Turkish Dermatology Association
• Dermatology and Venereal Diseases Association

PUBLICATIONS

• Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitisDermatol Ther. 2022 Jan;35(1):e15192 doi:10.1111/dth.15192. Epub 2021 Nov 15. PMID: 34743366. Salman A, Apti Sengun O, Acts M, Taşkapan O.
• Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life dataAustralian J Dermatol. 2021 Jun 22. doi: 10.1111/ajd.13656. Salman A, Aktas M, Apti Sengun O.
• Netherton syndrome: Temporary response to dupilumabPediatr Dermatol. 2020 Nov;37(6):1210-1211. doi: 10.1111/pde.14362. Epub 2020 Sep 19. PMID: 32951242. (2020) Aktas M, Salman A, Apti Sengun O, Comert Ozer E, Hosgoren Tekin S, Akin Cakici O, Demir G, Ergun T.
• Yellow Urticaria.Allergy Clin Immunol Pract. 2021 Jan;9(1):479-480. doi: 10.1016/j.jaip.2020.10.029. Epub 2020 Nov 3. PMID: 33153950 Puller OA, Sengun OA, Tekin SH, Salman A.
• Slime: A trending cause of isothiazolinone contact allergy in childrenContact Dermatitis. 2019 Jun;80(6):409-411. two: 10.1111/cod.13237. (2019) Salman, A., Demir, G., & Apti, O